InGeNA’s Independent Board Chair, Carl Stubbings, joined industry leaders from across the life sciences ecosystem for two days of insightful discussion, collaboration and forward-thinking conversations. One of the standout sessions was the Innovators Forum, where five emerging diagnostics companies pitched their technologies to an expert panel. The opportunity to receive strategic advice, build industry connections and gain commercialisation insights highlighted the critical role collaboration plays in accelerating innovation.
We would also like to acknowledge InGeNA members A/Prof Colman Taylor from HTAnalysts and Katie Battese Ellis from Illumina for chairing and facilitating workshops throughout the congress, helping to drive valuable conversations across the sector.Another highlight was hearing from InGeNA member Zoë Milgrom from Eugene, who joined a panel discussion on what meaningful healthcare innovation looks like in practice. Reflecting on the conversation, Zoë noted:
“What gave me hope was the fierce consensus: better-targeted testing, multidisciplinary care, and solutions designed with the people who need them most, not just for them.”
Her comments captured one of the strongest themes of the congress. Advancing healthcare outcomes requires solutions that are developed with patients at the centre and supported by collaboration across the entire healthcare ecosystem.
PTA-C/26 demonstrated the value of bringing together private and public pathology providers, clinicians, industry leaders, advocates and policymakers. There was a shared commitment to not only improve practice but also influence the policy settings needed to support innovation and better patient outcomes.
Thank you to the PTA team, Dean Whiting, Chami Lam and Madeline O’Donaghue, for delivering another outstanding event and creating a forum that continues to foster meaningful connections and important conversations.
As the sector continues to navigate complex healthcare challenges, one message was clear: no single organisation or stakeholder group can solve these issues alone. Collaboration remains the key to translating innovation into impact and shaping tomorrow’s standard of care
